실시간
FierceBiotechBial bails after Parkinson’s fail, axing asset over phase 2 missClinical OMICsGenome Wide Analysis Broadens Genetic Knowledge of AnxietyFierceBiotechGSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancerRoche MediaGSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer - Fierce BiotechLabiotechPharma in Spain: why global investors and innovators are moving inEndpoints NewsGSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6BeLifeExperience shapes the transformation of olfactory representations along the cortico-hippocampal pathway10x Genomics Blog10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan10x Genomics Blog10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan10x Genomics News10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan10x Genomics News10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan10x Genomics News10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com
BioWorld 2025년 12월 4일

CTAD 2025: The challenges of combination therapies for dementia

CTAD 2025: The challenges of combination therapies for dementia

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.